Notice: Publication of the Guidance Document: Certificates of Supplementary Protection

January 6, 2021

Our reference number : 20-118371-621

Health Canada is pleased to announce the fourth publication of the Guidance Document: Certificates of Supplementary Protection.

Since September 21, 2017, the Office of Patented Medicines and Liaison, within the Office of Submissions and Intellectual Property (OSIP), has administered sections 104 to 134 of the Patent Act and the Certificate of Supplementary Protection Regulations (CSP Regulations).

A new fourth version of the Certificate of Supplementary Protection (CSP) application form is now available for use effective immediately, which reflects the change described in this notice.

An amendment has been made to the CSP Regulations to add the United Kingdom to the list of prescribed countries under paragraph 6(1)(a), which came into force on January 6, 2021. The CSP application form and Guidance Document have now been amended to reflect this change.

Questions or concerns related to this Guidance Document should be directed to the Office of Patented Medicines and Liaison at:

E-mail: hc.opml-bmbl.sc@canada.ca

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: